cupure logo
Daraxonrasib halted tumor growth in 90% of patients in pancreatic cancer study
Habertürk
Health·

Daraxonrasib halted tumor growth in 90% of patients in pancreatic cancer study

Daraxonrasib halted tumor growth in 90% of patients in a clinical study of pancreatic cancer. Tumors shrank in about 60% of participants in one report; another said cancer was undetectable on scans in 8%.

Comments

Read this story in other languages

Similar News from External Sources

How we write our stories →

Cupure writes the day's most important stories in seven languages. The name comes from the French 'coupure de journal' — a newspaper clipping — our promise of concise, relevant news.

For advertising inquiries, content suggestions, or to flag a concern about a news item or content, you can reach us. We value your feedback. Contact form